Healthcare - Biotechnology - NASDAQ - GB
$ 35.66
0.82 %
$ 2.92 B
Market Cap
-18.67
P/E
CASH FLOW STATEMENT
-50.2 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
92.9 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Verona Pharma plc
| Net Income | -54.6 M |
| Depreciation & Amortization | 116 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 19 M |
| Change in Working Capital | -14 M |
| Others | -14.8 M |
| Free Cash Flow | -50.2 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | Dec-2007 | Dec-2006 | Dec-2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||||||||||||||
| Net Income | (54.6) | (68.7) | (55.6) | (65.1) | (51.4) | (30.6) | (34.1) | (7.4) | (13.3) | (5.9) | (4.6) | (4.2) | (2.9) | (2.9) | (2.6) | (2.2) | (2.6) | (1.3) | 12 K |
| Depreciation & Amortization | 0.1 | 0.6 | 0.6 | 0.6 | 0.7 | 0.1 | 0.2 | 76 K | 78.7 K | 82.4 K | 62 K | 49.1 K | 37.3 K | 32.4 K | 35.6 K | 27.8 K | 27.8 K | 3.92 K | 0 |
| Deferred Income Tax | (0.5) | 0 | (17.4) | (0.6) | 5.7 | 5.8 | 1.1 | 1.9 | 0.8 | 0.3 | 0.3 | 10.3 K | 40.4 K | 48.2 K | 34 K | 80 K | (0.1) | (0.3) | 0 |
| Stock Based Compensation | 19.0 | 14.1 | 25.4 | 22.2 | 3.2 | 3.7 | 3.9 | 0.7 | 0.6 | 0.3 | 0.3 | 0.1 | 0.3 | 64.8 K | 21 K | 57.1 K | 0.2 | 0.6 | 0 |
| Other Operating Activities | (0.3) | 4.8 | 0.2 | 18 K | (2.5) | (1.9) | (6.2) | (1.3) | 0.4 | 0.2 | 0.2 | 67.3 K | 0.2 | 42 K | 22.6 K | 39 K | 0.1 | 0.3 | 0 |
| Change in Working Capital | (14.0) | (10.7) | 13.4 | (2.1) | 45.9 K | (0.1) | 7.0 | (0.9) | 2.0 | (0.4) | 0.4 | (0.1) | 85.4 K | 0.3 | 90.6 K | 0.1 | 23.8 K | 39.2 K | 15.5 K |
| Cash From Operations | (50.2) | (59.9) | (33.3) | (45.1) | (44.3) | (23.0) | (28.0) | (6.9) | (9.4) | (5.5) | (3.4) | (4.1) | (2.4) | (2.6) | (2.6) | (2.0) | (2.4) | (0.7) | 3.44 K |
| INVESTING CASH FLOW | |||||||||||||||||||
| Capital Expenditures | 0 | 29 K | 12 K | 82 K | (0.4) | (0.3) | (0.3) | (0.2) | (0.2) | (0.3) | (0.2) | (0.1) | 43.5 K | 75.6 K | 40.4 K | 32.2 K | 33.7 K | 29.4 K | 0 |
| Other Items | 0 | 0 | 0 | 9.8 | 49.9 | 7.0 | (66.6) | 0.1 | 75 K | 37.6 K | 4.36 K | 32.6 K | 4.66 K | 12.3 K | 16.2 K | 0.2 | 2.8 | (2.5) | 46.5 K |
| Cash From Investing Activities | 0 | 29 K | 12 K | 9.7 | 49.6 | 6.7 | (66.9) | 51 K | (0.1) | (0.3) | (0.2) | 87.8 K | 38.8 K | 63.3 K | 24.3 K | 0.2 | 2.8 | (2.5) | 46.5 K |
| FINANCING CASH FLOW | |||||||||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 38.7 | 5.0 | 0 | 5.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (63.3) | (14.0) | (6.8) | (12.8) | 0 | 0 | (31.4) | (4.4) | 0 | 0 | 0 | 1 012.9 | 26.5 K | 83.3 K | 87.3 K | 0 | 0 | (0.7) | 86 K |
| Cash From Financing Activities | 92.9 | 140.8 | (6.1) | 192.3 | (0.6) | 1.09 | 85.5 | 50.8 | 0 | 20.4 | 3.0 | 1.6 | 3.3 | 1.3 | 3.3 | 3.6 | 0 | 3.3 | 1.6 |
| CHANGE IN CASH | |||||||||||||||||||
| Net Change In Cash | 43.9 | 79.4 | (39.6) | 157.6 | 4.1 | (14.8) | (11.3) | 44.7 | (9.5) | 14.6 | (0.6) | (2.5) | 0.8 | (1.3) | 0.6 | 1.8 | 0.4 | 0.2 | 1.7 |
| FREE CASH FLOW | |||||||||||||||||||
| Free Cash Flow | (50.2) | (59.9) | (33.3) | (45.2) | (44.7) | (23.3) | (28.3) | (7.1) | (9.6) | (5.9) | (3.6) | (4.2) | (2.5) | (2.6) | (2.7) | (2.0) | (2.4) | (0.7) | 3.44 K |